newsfilter
← Latest News
GlobeNewswire·

Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca

- Icosavax stockholders to receive $15.00 per share in cash at closing plus non-tradeable contingent value right (CVR) of up to $5.00 per share - - Representing a total equity value of up to $1.1 billion including the